Hunt for the RAGE Gene Announced: Russian Scientists Take on Gene Therapy Against Aging
Researchers are working on a drug designed to specifically block the receptor that activates cellular aging. If successful, it will be the world's first gene therapy tool that doesn't just mask age-related changes but shuts down their biological trigger.
Humanity has spent centuries trying to slow aging from the outside—with creams, diets, and hormonal cocktails. But the real lever has always been hidden inside cells. Now Russian scientists are targeting it with gene therapy. The goal is the RAGE gene, a receptor that acts as a molecular detonator for age-related destruction. If it can be silenced, the cell stops receiving the signal to age.
Not an Anti-Aging Cream, but a Genetic Knockout
On April 23, 2026, at the All-Russian Conference "For the Medicine of Healthy Longevity" in Saransk, Deputy Minister of Science and Higher Education Denis Sekirinsky announced the launch of an ambitious project. The Institute of Biology of Aging and Medicine has begun developing the world's first gene therapy drug that specifically blocks the RAGE receptor.
Sekirinsky explained the logic bluntly: "Activation of this gene triggers cell aging. Blocking it, on the contrary, can extend the cell's youth." According to the developers, the drug is intended to be not just another geroprotector, but a fundamentally new class of therapy—an intervention into the genetic program of aging.
In parallel, the institute is conducting a second project—exosome-based therapy for sarcopenia. Exosomes are extracellular vesicles that cells use for communication. Experiments in 2025 at the Petrovsky National Research Center for Surgery showed a striking picture: if exosomes from aging cells are transplanted into young cells, inflammation skyrockets and the cells rapidly deteriorate. Conversely, if exosomes from young cells are transplanted into old cells, rejuvenation occurs.
RAGE: The Molecular Switch Between Life and Frailty
RAGE is not some esoteric protein of interest only to a handful of gerontologists. It is a receptor from the immunoglobulin superfamily that sits on the cell surface and binds to advanced glycation end products (AGEs). These sticky molecular waste products accumulate in tissues with age and diabetes, causing oxidative stress and chronic inflammation.
Activation of the AGEs-RAGE axis triggers a cascade through the NF-kB signaling pathway—one of the main conductors of inflammatory processes in the body. The result: release of pro-inflammatory cytokines, cell damage, accelerated aging of blood vessels, neurons, and muscle tissue. Moreover, activated RAGE itself stimulates its own expression, creating a vicious cycle: more receptors → more inflammation → more damage → even more receptors.
Russian scientists, including researchers from Moscow State University, have already demonstrated the role of RAGE signaling in activating neutrophils upon contact with bacteria and cellular degradation products. This explains why the immune system begins to attack itself with age: RAGE switches it into a mode of chronic low-grade inflammation—the very inflammaging that gerontologists consider a key driver of age-related pathologies.
The idea of blocking this receptor with a gene therapy method is a qualitative leap. Pharmaceutical companies have already attempted to create small-molecule inhibitors of RAGE, but systemic effects on such a fundamental mechanism required either toxic doses or caused side effects on the kidneys and liver. Gene therapy promises to solve the problem differently: not by poisoning the receptor with chemicals, but by shutting down its production at the DNA level.
Between Kremlin Longevity and the Global Race
The project is not unfolding in a vacuum. It is embedded in the national project "New Technologies for Health Preservation" with a budget of over 2 trillion rubles. Deputy Prime Minister Tatyana Golikova stated back in 2025 that production of an anti-aging drug is planned to begin in 2028–2030.
The global context adds tension. On April 8, 2026, Boston-based Life Biosciences, co-founded by Harvard geneticist David Sinclair, announced raising $80 million for clinical trials of gene therapy for partial epigenetic reprogramming. Their drug ER-100 has already been injected into the first patient with glaucoma—the first-ever trial of a "rejuvenating" gene therapy in humans.
The strategies differ fundamentally. Sinclair uses the genes Octamer-4, Sox2, and Klf4—the "Yamanaka factors"—which roll back the cell's epigenetic clock to a younger state. This reprogramming is risky, with potential oncogenicity, so a "switch" based on the antibiotic doxycycline is built into the construct.
The Russian approach is fundamentally different. Instead of rewriting the entire epigenetic program of the cell, scientists target a specific receptor that acts as an antenna for aging signals. Block RAGE, and the cell stops hearing the command to age, but retains its identity. This is not rejuvenation in the sense of returning to an embryonic state, but rather protection from accelerated degradation.
Who Benefits and Who Gets Left Behind
The primary winner is public healthcare. The average life expectancy for Russian men is about 67 years. If a drug that blocks RAGE can delay age-related pathology by even 5–7 years, the economic impact on the pension system and healthcare would be comparable to launching a dozen new pharmaceutical plants.
The Institute of Biology of Aging and Medicine has a chance to become a global center of competence. The scientific base on RAGE among Russian groups is already strong: publications on neutrophils, aptamers against RAGE, and the receptor's role in neuroinflammation. A gene therapy drug is a logical continuation of this line, and if it reaches the clinic, Russia will stake a priority in a niche where no approved drug currently exists.
Pharmaceutical companies working with geroprotectors—metformin, rapamycin, senolytics—will gain a competitor of a fundamentally different class. Small-molecule drugs require continuous intake and hit multiple targets, causing side effects. A one-time gene therapy that turns off RAGE for years will upend the anti-aging market economy: instead of a lifelong subscription to pills, a single injection.
Paradoxically, private anti-aging clinics lose out. If the state begins producing gene therapy for aging under a national project, the market for "rejuvenating IV drips" and unverified supplements will collapse. Patients will vote with their feet for therapy with a proven mechanism of action, even if it is only available through quotas.
What's Next: 2028–2030 and Beyond
The first stage is preclinical trials on animal models. The Institute of Biology of Aging and Medicine must show that blocking RAGE is safe in the long term: the receptor is involved in the immune response, and its complete shutdown could make the body vulnerable to infections. Here, a sweet spot must be found—not a gene knockout, but partial suppression of expression.
The second stage is Phase I/II in humans. Given that the FDA does not recognize "aging" as a disease, Russian researchers, like Life Biosciences, will have to choose a specific age-associated indication. Most likely, this will be diabetic nephropathy or a neurodegenerative disease—conditions with a well-studied role of RAGE signaling and objective biomarkers.
The third stage is production scaling. Here, Russia relies on existing infrastructure: the Gamaleya Center is building a plant for mRNA vaccines, Vector is refining a rapid synthesis platform, and Pirogov Russian National Research Medical University is launching production of gene therapy drugs in 2027. If production capacities are fully operational by 2028, the anti-RAGE drug could be the first product to be mass-produced.
The most interesting aspect is the international reaction. Sinclair's Life Biosciences and the Russian Institute of Biology of Aging are on parallel courses: one rewrites epigenetics, the other turns off the receptor for age-related inflammation. These two approaches do not compete but complement each other. One can envision a future where a patient receives a combination: anti-RAGE to stop degradation and partial reprogramming to restore already damaged tissues.
But that horizon is still years of trials, regulatory battles, and inevitable skeptical publications away. For now, we have a concrete statement from the Deputy Minister in Saransk, a working scientific base on RAGE, and a clear date on the horizon—2028–2030. In the race against aging, this is not an abstract "someday," but a plan with a budget, an executing institute, and a production roadmap. The cellular clock is ticking. And it seems someone has finally picked up a screwdriver.
— Editorial Team
